帕金森病前驱期嗅觉减退与多巴胺转运体缺陷队列的转化研究
该研究基于PARS队列,对203例嗅觉减退者和100例嗅觉正常者进行嗅觉测试、DAT成像及临床随访。结果显示,基线嗅觉减退合并DAT缺陷者4年内67%转化为帕金森病,相对风险为17.47(95%CI 7.02-43.45),且DAT结合年下降约5%,与早期帕金森病相似。
要点
- 嗅觉减退合并DAT缺陷者4年转化帕金森病风险高,相对风险17.47。
- 基线DAT缺陷者4年DAT结合下降20.23%,年均约5%。
- 嗅觉测试联合DAT成像可高效识别前驱期帕金森病高危个体。
核心结论
- 嗅觉减退合并DAT缺陷对4年内转化为帕金森病具有高度预测价值。
- 该类个体DAT结合年下降约5%,与早期帕金森病相似,为预防研究提供框架。
研究设计与样本
- PARS前瞻性队列,社区招募203例嗅觉减退者和100例嗅觉正常者。
- 基线进行嗅觉测试,第2年和第4年进行DAT成像,并每年临床随访。
- 185例嗅觉减退者和95例嗅觉正常者至少完成1次随访。
主要发现
- 21例基线嗅觉减退合并DAT缺陷者中14例(67%)4年内转化为帕金森病。
- 22例DAT不确定者中2例(9%)转化,109例无DAT缺陷者中3例(2.8%)转化。
- 嗅觉减退合并DAT缺陷者转化帕金森病的相对风险为17.47(95%CI 7.02-43.45)。
关键数值与推荐
- DAT缺陷定义为年龄预期最低壳核结合比值≤65%。
- DAT不确定范围定义为>65%-80%,无缺陷定义为>80%。
临床怎么用
- 对嗅觉减退人群可考虑DAT成像以识别前驱期帕金森病高危个体。
- 嗅觉减退合并DAT缺陷者应密切临床随访,便于早期干预研究。
局限性
- 样本量有限,尤其DAT缺陷组仅21例。
- 随访时间4年,长期转化率未知。
- 研究人群来自社区,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Detecting individuals at risk for Parkinson disease (PD) during the prodromal phase could clarify disease mechanisms and allow for treatment earlier in the disease process to possibly slow or prevent the onset of motor PD. OBJECTIVE: To determine if the combination of smell identification testing followed by dopamine transporter (DAT) imaging can accurately and efficiently identify individuals from the general population at risk for conversion to a clinical diagnosis of PD. DESIGN, SETTING, AND PARTICIPANTS: Participants were identified from the community by olfactory testing assessed longitudinally with DAT imaging 2 and 4 years after baseline and by annual clinical follow-up to determine whether they had clinical evidence to establish a PD diagnosis. Participants were contacted by mail and completed olfactory testing at home. Longitudinal follow-up of clinical measures and DAT imaging occurred at specialty centers. There were 203 hyposmic and 100 normosmic participants. A total of 185 hyposmic and 95 normosmic individuals had at least 1 follow-up visit, and 152 hyposmic participants (82.2%) were either observed for 4 years or converted to PD during follow-up. MAIN OUTCOMES AND MEASURES: Percentage of individuals with hyposmia and a DAT deficit that converted to PD and the change in PD clinical scale scores (Unified Parkinson's Disease Rating Scale) and DAT imaging during 4-year follow-up. RESULTS: Of 280 total participants, 140 (50.0%) were male, and the mean (SD) age of the cohort was 63 (8.7) years. Among 21 participants with hyposmia and a DAT deficit (65% or less of age-expected lowest putamen binding ratio) at baseline, 14 (67%) converted to PD at 4 years compared with 2 of 22 participants (9%) with a DAT in an indeterminate range (greater than 65%-80%) and 3 of 109 participants (2.8%) with no DAT deficit (greater than 80%) at baseline. Individuals with a baseline DAT deficit experienced a 4-year decline in DAT binding of 20.23% (SD, 15.04%) compared with 3.68% (SD, 18.36%) and 5.45% (SD, 13.58%) for participants with an indeterminate and no DAT deficit, respectively (P = .002). The relative risk of conversion to a diagnosis of PD in hyposmic individuals with a DAT deficit was 17.47 (95% CI, 7.02-43.45) compared with individuals with either indeterminate or no DAT deficit. CONCLUSIONS AND RELEVANCE: The combination of hyposmia and DAT deficit was highly predictive of conversion to PD within 4 years of clinical follow-up. Individuals with hyposmia and a DAT deficit had a 5% reduction in DAT binding annually, similar to early PD. These results provide a framework for planning disease prevention studies in PD.
引用
- Jennings D, Siderowf A, Stern M, et al. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. JAMA Neurol. 2017. PMID: 28595287. doi:10.1001/jamaneurol.2017.0985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。